
Regeneron Pharmaceuticals (REGN)
Order type
Buy in
Order amount
Est. shares
0 shares
Buy Regeneron Pharmaceuticals (REGN) Stock
Start investing in Regeneron Pharmaceuticals (REGN)
About Regeneron Pharmaceuticals (REGN)
Market cap | $56.68B |
Yesterday's volume | 1.02M |
Revenue (TTM) | $14.09B |
Avg. daily volume | 1.36M |
EBITDA (TTM) | $4.46B |
Open | $520.21 |
Price / earnings ratio | 13.36x |
Yesterday's range | $518.9 - $526.08 |
Debt / equity | 9.2x |
52 week range | $476.49 - $1.21K |
5 year debt / equity | 13.45x |
Beta (LTM) | 0.7x |
Interest coverage | 75.61x |
Dividend & yield | $0.88 (0.17%) |
Current ratio | 4.93x |
Ex-dividend date | — |
Next earnings | Aug 1, 2025 |
Dividend payable date | — |
Regeneron Pharmaceuticals Stock Rating
Regeneron Pharmaceuticals Stock News
View all



Frequently Asked Questions (FAQ)
How to buy REGN stock on Public
- 1
Sign up for a brokerage account on Public
It’s easy to get started. You can sign up for an account directly on our website or by downloading the Public app for iOS or Android.
- 2
Add funds to your Public account
There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.
- 3
Choose how much you'd like to invest in REGN stock
Navigate to the Explore page. Then, type REGN into the search bar. When you see REGN stock appear in the results, tap it to open up the purchase screen.
- 4
Manage your investments in one place
You can find your newly purchased REGN stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets.
Regeneron Pharmaceuticals Stock Earnings
The value each REGN share was expected to gain vs. the value that each REGN share actually gained.
Regeneron Pharmaceuticals (REGN) reported Q1 2025 earnings per share (EPS) of $8.22, missing estimates of $8.82 by 6.80%. In the same quarter last year, Regeneron Pharmaceuticals's earnings per share (EPS) was $9.55. Regeneron Pharmaceuticals is expected to release next earnings on 08/01/2025, with an earnings per share (EPS) estimate of $8.57.